ERBB2 and gastric cancer: Although anti-HER2 drugs such as trastuzumab and lapatinib are being used as molecularly targeted agents for gastric cancer patients with HER2 overexpression and patients responded clinically, acquired resistance to these anti-HER2 drugs has been observed in a subset of gastric cancer patients following chronic exposure [7].